SCHEMBL30002873

SCHEMBL30002873

COc1cc(OC)c2c(=O)c(OC(=O)c3ccc(OCc4ccccc4)cc3)c(-c3ccc(OCc4ccccc4)cc3)oc2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.71
ADORA3 P0DMS8 7/20 0.59
SLC22A2 O15244 1/20 0.58
SLC22A1 O15245 1/20 0.58
ALDH1A1 P00352 2/20 0.53
CYP1A2 P05177 2/20 0.53
NPC1 O15118 1/20 0.53
CYP2C9 P11712 1/20 0.53
HPGD P15428 1/20 0.53
CYP2C19 P33261 1/20 0.53
RAB9A P51151 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
ABCG2 Q9UNQ0 6/20 0.52
ABCB1 P08183 4/20 0.51
ABCC1 P33527 3/20 0.51
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
CYP3A4 P08684 1/20 0.51
MAPK1 P28482 1/20 0.51
KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21275449 1.00 PPARG (0.71) PPARGADORA3SLC22A2SLC22A1ALDH1A1
SCHEMBL30002790 0.96 PPARG (0.68) PPARGADORA3SLC22A2SLC22A1ALDH1A1
SCHEMBL21275482 0.96 PPARG (0.68) PPARGADORA3SLC22A2SLC22A1ALDH1A1
SCHEMBL21275469 0.84 ABCG2 (0.74) PPARGADORA3SLC22A2SLC22A1ALDH1A1
SCHEMBL30002869 0.84 ABCG2 (0.74) PPARGADORA3SLC22A2SLC22A1ALDH1A1
SCHEMBL28539389 0.81 PPARG (0.61) PPARGADORA3SLC22A2SLC22A1ALDH1A1
SCHEMBL30002854 0.80 ABCG2 (0.74) PPARGADORA3SLC22A2SLC22A1ALDH1A1
SCHEMBL5792138 0.80 ABCG2 (0.74) PPARGADORA3SLC22A2SLC22A1ALDH1A1
SCHEMBL7551823 0.80 PPARG (0.92) PPARGADORA3SLC22A2SLC22A1ALDH1A1
SCHEMBL16151312 0.79 PPARG (0.71) PPARGADORA3SLC22A2SLC22A1ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115213-A1 SYNTHETIC ROCAGLATES WITH BROAD-SPECTRUM ANTIVIRAL ACTIVITIES AND USES THEREOF MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2026-04-30 US disclosed
EP-4322940-A1 SYNTHETIC ROCAGLATES WITH BROAD-SPECTRUM ANTIVIRAL ACTIVITIES AND USES THEREOF Memorial Sloan-Kettering Cancer Center (US) 2024-02-21 EP disclosed
WO-2022221519-A1 SYNTHETIC ROCAGLATES WITH BROAD-SPECTRUM ANTIVIRAL ACTIVITIES AND USES THEREOF MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2022-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115213-A1 SYNTHETIC ROCAGLATES WITH BROAD-SPECTRUM ANTIVIRAL ACTIVITIES AND USES THEREOF SARS1, RNGTT, NSUN3 PPARG 2049/4885ADORA3 2159/4885SLC22A2 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.